Lutathera®
Neuroendocrine Tumors
Key Facts
About Novartis
Novartis is a global pharmaceutical leader with a mission to reimagine medicine to improve and extend lives. With a market cap of $290.10B, it operates across 118 countries, reaching over 300 million patients annually. Its strategy focuses on delivering high-value medicines for society's greatest disease burdens through technology leadership in R&D and novel access approaches, powered by a diversified portfolio across oncology, cardiovascular, immunology, neuroscience, and rare diseases.
View full company profileTherapeutic Areas
Other Neuroendocrine Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| Oncology Focus (Neuroendocrine Tumors) | Curium Pharma | Not Specified |
| Zanzalintinib (XL092) | Exelixis | Phase 3 |
| LNC1010 / LNC1014 | Lantheus Holdings | Phase 1 |
| CRN01941 | Crinetics Pharmaceuticals | Phase 1 |